Abstract
Cryptosporidiosis caused by Cryptosporidium spp. is an important diarrhoeal disease observed in farm animals and humans, especially in young or immunocompromised individuals. A novel cell culture assay for testing extracts and pure compounds against Cryptosporidium parvum in 96-well microplate format was established and evaluated. It is based on previously described indirect fluorescent antibody techniques and was optimised for higher sample throughput. Rapid assessment of minimal inhibitory concentrations (MICs) was done by checking each well microscopically for the presence or absence of parasite stages. As a novelty, parasite development was quantified by enumeration of clusters of secondary infection (CSI), which typically appeared upon infection with a distinct parasite inoculum after a defined incubation time. Host cell (HCT-8) viability was measured by an integrated non-destructive water-soluble tetrazolium salt assay (WST-1), which facilitated discrimination of antiparasitic activity from possible cytotoxic effects of a test compound against the host cells. Host cell viability was regarded unimpaired when cultures had 75% or more viability when compared to control cultures without test substance. In this study, a maximum density of distinguishable CSI was obtained when cultures were infected with 2.5 × 103 oocysts and incubated for 48 h. The applicable inoculum has to be optimised for each batch of oocysts and before each experimental series. Parasite development was inhibited completely by monensin at 134 nM and silymarin at 50 mg/mL. These concentrations were non-toxic to the host cells and comparable to literature data. The percentages of parasite inhibition were determined for monensin and a 50% inhibitory concentration (IC50) of 36.6 nM (27.4–45.5) and a 90% inhibitory concentration of 65.9 nM (54.8–90.2) were calculated. The introduced assay is economic because relatively low parasite numbers may be used. If MICs are determined, evaluation is fast, as each well is viewed only briefly under the fluorescence microscope for presence or absence of CSI. Furthermore it is highly critical because only full parasite inhibition is assessed. Counting of CSI is more laborious and time-consuming, but it allows calculation of parasite inhibition rates and parameters like the half maximal inhibitory concentration (IC50). This assay shall be used to assess anticryptosporidial activities of various plant waste materials and by-products from the food and the pharmaceutical industries in the course of the EU project SAFEWASTES. Comparison with in vivo models should be performed to further corroborate the results. Automated evaluation by flow cytometry might facilitate higher sample throughput and reduce operator bias.
Similar content being viewed by others
References
Armson A, Meloni BP, Reynoldson JA, Thompson RC (1999) Assessment of drugs against Cryptosporidium parvum using a simple in vitro screening method. FEMS Microbiol Lett 178:227–233
Bagavan A, Rahuman AA, Kamaraj C, Kaushik NK, Mohanakrishnan D, Sahal D (2011a) Antiplasmodial activity of botanical extracts against Plasmodium falciparum. Parasitol Res 108:1099–1109
Bagavan A, Rahuman AA, Kaushik NK, Sahal D (2011b) In vitro antimalarial activity of medicinal plant extracts against Plasmodium falciparum. Parasitol Res 108:15–22
Brandelli CL, Giordani RB, De Carli GA, Tasca T (2009) Indigenous traditional medicine: in vitro anti-giardial activity of plants used in the treatment of diarrhea. Parasitol Res 104:1345–1349
Cai X, Woods KM, Upton SJ, Zhu G (2005) Application of quantitative real-time reverse transcription-PCR in assessing drug efficacy against the intracellular pathogen Cryptosporidium parvum in vitro. Antimicrob Agents Chemother 49:4437–4442
Chon SK, Kim NS (2005) Evaluation of silymarin in the treatment on asymptomatic Giardia infections in dogs. Parasitol Res 97:445–451
Derda M, Hadas E, Thiem B (2009) Plant extracts as natural amoebicidal agents. Parasitol Res 104:705–708
Di Giovanni GD, LeChevallier MW (2005) Quantitative-PCR assessment of Cryptosporidium parvum cell culture infection. Appl Environ Microbiol 71:1495–1500
EMEA (2007) European Public Assessment Report (EPAR) Halocur. European Medicines Agency, London. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/veterinary/000040/WC500064767.pdf. Accessed 27 February 2011
Flora K, Hahn M, Rosen H, Benner K (1998) Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol 93:139–143
Freshney RI (2005) Culture of animal cells—a manual of basic technique, 5th edn. Wiley, London, pp 117–118
Godiwala NT, Vandewalle A, Ward HD, Leav BA (2006) Quantification of in vitro and in vivo Cryptosporidium parvum infection by using real-time PCR. Appl Environ Microbiol 72:4484–4488
Hijjawi N (2010) Cryptosporidium: new developments in cell culture. Exp Parasitol 124:54–60
Hijjawi NS, Meloni BP, Morgan UM, Thompson RC (2001) Complete development and long-term maintenance of Cryptosporidium parvum human and cattle genotypes in cell culture. Int J Parasitol 31:1048–1055
Hijjawi NS, Meloni BP, Ryan UM, Olson ME, Thompson RC (2002) Successful in vitro cultivation of Cryptosporidium andersoni: evidence for the existence of novel extracellular stages in the life cycle and implications for the classification of Cryptosporidium. Int J Parasitol 32:1719–1726
Hijjawi NS, Meloni BP, Ng'anzo M, Ryan UM, Olson ME, Cox PT, Monis PT, Thompson RC (2004) Complete development of Cryptosporidium parvum in host cell-free culture. Int J Parasitol 34:769–777
Joachim A (2004) Human cryptosporidiosis: an update with special emphasis on the situation in Europe. J Vet Med B Infect Dis Vet Public Health 51:251–259
Joachim A, Eckert E, Petry F, Bialek R, Daugschies A (2003) Comparison of viability assays for Cryptosporidium parvum oocysts after disinfection. Vet Parasitol 111:47–57
Karanis P, Kourenti C, Smith H (2007) Waterborne transmission of protozoan parasites: a worldwide review of outbreaks and lessons learnt. J Water Health 5:1–38
Lacharme L, Villar V, Rojo-Vazquez FA, Suarez S (2004) Complete development of Cryptosporidium parvum in rabbit chondrocytes (VELI cells). Microbes Infect 6:566–571
Lallemand M, Villeneuve A, Belda J, Dubreuil P (2006) Field study of the efficacy of halofuginone and decoquinate in the treatment of cryptosporidiosis in veal calves. Vet Rec 159:672–676
Lindsay DS, Woods KM, Upton SJ, Blagburn BL (2000) Activity of decoquinate against Cryptosporidium parvum in cell cultures and neonatal mice. Vet Parasitol 89:307–311
MacDonald LM, Sargent K, Armson A, Thompson RC, Reynoldson JA (2002) The development of a real-time quantitative-PCR method for characterisation of a Cryptosporidium parvum in vitro culturing system and assessment of drug efficacy. Mol Biochem Parasitol 121:279–282
Machado M, Dinis AM, Salgueiro L, Cavaleiro C, Custodio JB, Sousa MC (2010) Anti-Giardia activity of phenolic-rich essential oils: effects of Thymbra capitata, Origanum virens, Thymus zygis subsp. sylvestris, and Lippia graveolens on trophozoites growth, viability, adherence, and ultrastructure. Parasitol Res 106:1205–1215
McDonald V, Stables R, Warhurst DC, Barer MR, Blewett DA, Chapman HD, Connolly GM, Chiodini PL, McAdam KP (1990) In vitro cultivation of Cryptosporidium parvum and screening for anticryptosporidial drugs. Antimicrob Agents Chemother 34:1498–1500
Mead J, McNair N (2006) Antiparasitic activity of flavonoids and isoflavones against Cryptosporidium parvum and Encephalitozoon intestinalis. FEMS Microbiol Lett 259:153–157
Moore DA, Atwill ER, Kirk JH, Brahmbhatt D, Herrera AL, Hou L, Singer MD, Miller TD (2003) Prophylactic use of decoquinate for infections with Cryptosporidium parvum in experimentally challenged neonatal calves. J Am Vet Med Assoc 223:839–845
Najdrowski M, Heckeroth AR, Wackwitz C, Gawlowska S, Mackenstedt U, Kliemt D, Daugschies A (2007a) Development and validation of a cell culture based assay for in vitro assessment of anticryptosporidial compounds. Parasitol Res 101:161–167
Najdrowski M, Joachim A, Daugschies A (2007b) An improved in vitro infection model for viability testing of Cryptosporidium parvum oocysts. Vet Parasitol 150:150–154
Navetat H, Cantaloube F (2003) Decoquinate to control cryptosporidiosis infestations in ruminants. Goat Connection. Khimaira Inc., Luray. Available at http://goatconnection.com/articles/publish/printer_143.shtml. Accessed 27 February 2011
Putignani L, Sanderson SJ, Russo C, Kissinger J, Menichella D, Wastling J (2009) Proteomic and genomic approaches to understanding the 'power plant' of Cryptosporidium. In: Ortega-Pierres G, Cacciò S, Fayer R, Mank TG, Smith HV, Thompson RCA (eds) Giardia and Cryptosporidium— from molecules to disease. CABI, Oxfordshire, p 354
Ricketts AP (1992) Eimeria tenella: growth and drug sensitivity in tissue culture under reduced oxygen. Exp Parasitol 74:463–469
Rochelle PA, Ferguson DM, Johnson AM, De LR (2001) Quantitation of Cryptosporidium parvum infection in cell culture using a colorimetric in situ hybridization assay. J Eukaryot Microbiol 48:565–574
Rochelle PA, Marshall MM, Mead JR, Johnson AM, Korich DG, Rosen JS, De LR (2002) Comparison of in vitro cell culture and a mouse assay for measuring infectivity of Cryptosporidium parvum. Appl Environ Microbiol 68:3809–3817
Saller R, Meier R, Brignoli R (2001) The use of silymarin in the treatment of liver diseases. Drugs 61:2035–2063
Schets FM, Engels GB, During M, de Roda Husman AM (2005) Detection of infectious Cryptosporidium oocysts by cell culture immunofluorescence assay: applicability to environmental samples. Appl Environ Microbiol 71:6793–6798
Shahiduzzaman M, Dyachenko V, Obwaller A, Unglaube S, Daugschies A (2009) Combination of cell culture and quantitative PCR for screening of drugs against Cryptosporidium parvum. Vet Parasitol 162:271–277
Slifko TR, Friedman D, Rose JB, Jakubowski W (1997) An in vitro method for detecting infectious Cryptosporidium oocysts with cell culture. Appl Environ Microbiol 63:3669–3675
Slifko TR, Huffman DE, Rose JB (1999) A most-probable-number assay for enumeration of infectious Cryptosporidium parvum oocysts. Appl Environ Microbiol 65:3936–3941
Slifko TR, Huffman DE, Dussert B, Owens JH, Jakubowski W, Haas CN, Rose JB (2002) Comparison of tissue culture and animal models for assessment of Cryptospridium parvum infection. Exp Parasitol 101:97–106
United Press International (2010) Water parasite sickens thousands in Sweden. United Press International Inc., Washington DC. Available at http://www.upi.com/Top_News/World-News/2010/11/29/Water-parasite-sickens-thousands-in-Sweden/UPI-56851291061398/. Accessed 27 February 2011
Upton S (2003) Cryptosporidium: they probably taste like chicken. In: Thompson RCA, Armson A, Ryan UM (eds) Cryptosporidium: from molecules to disease. Elsevier, Amsterdam, pp 3–7
Villacorta I, Peeters JE, Vanopdenbosch E, res-Mazas E, Theys H (1991) Efficacy of halofuginone lactate against Cryptosporidium parvum in calves. Antimicrob Agents Chemother 35:283–287
Villacorta I, de Graaf D, Charlier G, Peeters JE (1996) Complete development of Cryptosporidium parvum in MDBK cells. FEMS Microbiol Lett 142:129–132
Woods KM, Nesterenko MV, Upton SJ (1995) Development of a microtitre ELISA to quantify development of Cryptosporidium parvum in vitro. FEMS Microbiol Lett 128:89–94
Woods KM, Nesterenko MV, Upton SJ (1996) Efficacy of 101 antimicrobials and other agents on the development of Cryptosporidium parvum in vitro. Ann Trop Med Parasitol 90:603–615
Wu L, Chen SX, Jiang XG, Shen YJ, Lu ZX, Tu GH, Fu XL, Cao JP (2009) Effect of select medium supplements on in vitro development of Cryptosporidium andersoni in HCT-8 cells. Parasitol Res 105:1419–1424
Wu L, Jiang XG, Shen YJ, Lu ZX, Tu GH, Fu XL, Chen SX, Cao JP (2011) Efficacy of ginkgolic acids against Cryptosporidium andersoni in cell culture. Parasitol Res 109:1475–1479
Xiao L, Morgan UM, Limor J, Escalante A, Arrowood M, Shulaw W, Thompson RC, Fayer R, Lal AA (1999) Genetic diversity within Cryptosporidium parvum and related Cryptosporidium species. Appl Environ Microbiol 65:3386–3391
Yang S, Healey MC, Du C, Zhang J (1996) Complete development of Cryptosporidium parvum in bovine fallopian tube epithelial cells. Infect Immun 64:349–354
Yoder JS, Beach MJ (2010) Cryptosporidium surveillance and risk factors in the United States. Exp Parasitol 124:31–39
You X, Arrowood MJ, Lejkowski M, Xie L, Schinazi RF, Mead JR (1996) A chemiluminescence immunoassay for evaluation of Cryptosporidium parvum growth in vitro. FEMS Microbiol Lett 136:251–256
Acknowledgements
Klaus Teichmann is greatly indebted to Prof. Dr. Arwid Daugschies (Institute of Parasitology, Faculty for Veterinary Medicine, University Leipzig, Germany) and his team for an introduction to in vitro assays with C. parvum and to Prof. Dr. Ute Mackenstedt (Institute of Zoology, Faculty of Natural Sciences, University Hohenheim, Germany) for kind provision of antibodies. This research was funded by the sixth Framework Program of the European Community (project SAFEWASTES, contract no. FOOD-CT-2005-513949).
Ethical standards
The experiments comply with the current laws of Austria.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Teichmann, K., Kuliberda, M., Schatzmayr, G. et al. In vitro determination of anticryptosporidial activity of phytogenic extracts and compounds. Parasitol Res 111, 231–240 (2012). https://doi.org/10.1007/s00436-012-2824-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00436-012-2824-y